Skip to main content
Top
Published in: Langenbeck's Archives of Surgery 2/2022

01-03-2022 | Obesity | Original Article

GLP-1: 10-year follow-up after Roux-en-Y gastric bypass

Authors: Camila Carvalho, Aglécio Luiz de Souza, Gisele Almeida Batista, Louise Franciscato Trivelato Duran, Débora Puzzi Fernandes, Viviane Bressane Claus Molina, Raquel Gonçalves, Joelma Silvia Giorgetti, Elintom Adami Chaim, Sarah Monte Alegre

Published in: Langenbeck's Archives of Surgery | Issue 2/2022

Login to get access

Abstract

Purpose

Glucagon-like peptide-1 (GLP-1) is a hormone widely studied in the short-term postoperative follow-up of Roux-en-Y gastric bypass due to its elevation and association with improvement of the glucose metabolism, but there are few studies in 10 years after RYGB follow-up with the same patient.

Methods

Twenty morbidity obesity patients were submitted to RYGB; these patients were divided into two groups: normal glucose-tolerant morbidly obese patients (NGT) 11 patients and abnormal glucose metabolism morbidly obese patients (AGM) 9 patients. Oral glucose tolerance test (OGTT) was done during four different periods: T1 (first evaluation), T2 (pre-surgery), T3 (9 months after surgery) and T4 (10 years after surgery).

Results

Groups were matched for age and gender, and as NGT and AGM had BMI of 46.31 ± 5.03 kg/m2 and 50.87 ± 10.31 kg/m2. After 10 years of RYGB, they were obesity grade I with BMI for NGT 32.45 ± 4.99 kg/m2 and AGM 34.85 ± 4.46 kg/m2. Plasma glucose levels decreased NGT group at T4 period had a significant reduction at 120 min after OGTT for NGT 55.49 ± 17.15 mg/dL (p˂0.001). Insulin levels changed from T1 to T4 for the NGT group. GLP-1 curves were statistically different between the NGT and AGM groups. The AGM group had a higher mean for GLP-1 secretion at T4 period and at 30 min of OGTT 63.85 ± 37.98 pmol/L when compared to NGT 50.73 ± 24.82 pmol/L with AGM > NGT with p˂0.001.

Conclusion

Evaluation of the same patient during 4 different periods shows that, even with weight regain, after 10-years of RYGB high levels of GLP-1 remained which can be associated with metabolic improvement especially at the NGT group.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B et al (2004) Lifestyle, diabetes and cardiovascular risk factor ten years after bariatric surgery. N Engl J Med 351:2683–2693PubMed Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B et al (2004) Lifestyle, diabetes and cardiovascular risk factor ten years after bariatric surgery. N Engl J Med 351:2683–2693PubMed
2.
go back to reference Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD et al (2007) Long-term mortality after gastric bypass surgery. N Engl J Med 357:753–761PubMed Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD et al (2007) Long-term mortality after gastric bypass surgery. N Engl J Med 357:753–761PubMed
3.
go back to reference Kashyap SR, Bhatt DL, Wolski K, Watanabe RM, Abdul-Ghani M, Abood B et al (2013) Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care 36:2175–2182PubMedPubMedCentral Kashyap SR, Bhatt DL, Wolski K, Watanabe RM, Abdul-Ghani M, Abood B et al (2013) Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care 36:2175–2182PubMedPubMedCentral
4.
go back to reference Holst J, Madsbad S (2016) Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor. Surg Obes Relat Dis 12:1236–1242PubMed Holst J, Madsbad S (2016) Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor. Surg Obes Relat Dis 12:1236–1242PubMed
5.
go back to reference Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K et al (2004) Bariatric surgery: a systematic review and meta-analysis. JAMA 292:1724–1737PubMed Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K et al (2004) Bariatric surgery: a systematic review and meta-analysis. JAMA 292:1724–1737PubMed
6.
go back to reference Laferrère B, Heshka S, Wang K, Khan Y, McGinty J, Teixeira J, Hart AB, Olivan B (2007) Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 30:1709–1716PubMed Laferrère B, Heshka S, Wang K, Khan Y, McGinty J, Teixeira J, Hart AB, Olivan B (2007) Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 30:1709–1716PubMed
7.
go back to reference Jørgensen NB, Dirksen C, Bojsen-Møller KN, Jacobsen SH, Worm D, Hansen DL, Kristiansen VB, Naver L, Madsbad S, Holst JJ (2013) Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes 62(9):3044–3052. https://doi.org/10.2337/db13-0022CrossRefPubMedPubMedCentral Jørgensen NB, Dirksen C, Bojsen-Møller KN, Jacobsen SH, Worm D, Hansen DL, Kristiansen VB, Naver L, Madsbad S, Holst JJ (2013) Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes 62(9):3044–3052. https://​doi.​org/​10.​2337/​db13-0022CrossRefPubMedPubMedCentral
8.
go back to reference Dirksen C, Bojsen-Møller KN, Jørgensen NB, Jacobsen SH, Kristiansen VB, Naver LS, Hansen DL, Worm D, Holst JJ, Madsbad S (2013) Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass. Diabetologia 56(12):2679–2687. https://doi.org/10.1007/s00125-013-3055-1CrossRefPubMed Dirksen C, Bojsen-Møller KN, Jørgensen NB, Jacobsen SH, Kristiansen VB, Naver LS, Hansen DL, Worm D, Holst JJ, Madsbad S (2013) Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass. Diabetologia 56(12):2679–2687. https://​doi.​org/​10.​1007/​s00125-013-3055-1CrossRefPubMed
9.
go back to reference Bojanowska E (2005) Physiology and pathophysiology of glucagon-like peptide-1 (GLP-1): the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity, and stress. Med Sci Monit 11:RA271–RA278PubMed Bojanowska E (2005) Physiology and pathophysiology of glucagon-like peptide-1 (GLP-1): the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity, and stress. Med Sci Monit 11:RA271–RA278PubMed
10.
go back to reference Gutzwiller JP, Degen L, Heuss L, Beglinger C (2004) Glucagon-like peptide 1 (GLP-1) and eating. Physiol Behav 82:17–19PubMed Gutzwiller JP, Degen L, Heuss L, Beglinger C (2004) Glucagon-like peptide 1 (GLP-1) and eating. Physiol Behav 82:17–19PubMed
11.
go back to reference Knop FK, Aaboe K, Vilsbøll T, Vølund A, Holst JJ, Krarup T et al (2012) Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes Metab 14:500–510PubMed Knop FK, Aaboe K, Vilsbøll T, Vølund A, Holst JJ, Krarup T et al (2012) Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes Metab 14:500–510PubMed
12.
go back to reference Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87:1409–1439PubMed Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87:1409–1439PubMed
13.
go back to reference Jiménez A, Casamitjana R, Flores L, Delgado S, Lacy A, Vidal J (2013) GLP-1 and the long-term outcome of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery in morbidly obese subjects. Ann Surg 257:894–899PubMed Jiménez A, Casamitjana R, Flores L, Delgado S, Lacy A, Vidal J (2013) GLP-1 and the long-term outcome of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery in morbidly obese subjects. Ann Surg 257:894–899PubMed
14.
go back to reference de Carvalho CP, Marin DM, de Souza AL, Pareja JC, Chaim EA, de Barros MS et al (2009) GLP-1 and adiponectin: effect of weight loss after dietary restriction and gastric bypass in morbidly obese patients with normal and abnormal glucose metabolism. Obes Surg 19:313–320PubMed de Carvalho CP, Marin DM, de Souza AL, Pareja JC, Chaim EA, de Barros MS et al (2009) GLP-1 and adiponectin: effect of weight loss after dietary restriction and gastric bypass in morbidly obese patients with normal and abnormal glucose metabolism. Obes Surg 19:313–320PubMed
19.
go back to reference Dar MS, Chapman WH 3rd, Pender JR, Drake AJ 3rd, O’Brien K, Tanenberg RJ et al (2012) GLP-1 response to a mixed meal: What happens ten years after Roux-en Y Gastric Bypass (RYGB)? Obes Surg 22:1077–1083PubMed Dar MS, Chapman WH 3rd, Pender JR, Drake AJ 3rd, O’Brien K, Tanenberg RJ et al (2012) GLP-1 response to a mixed meal: What happens ten years after Roux-en Y Gastric Bypass (RYGB)? Obes Surg 22:1077–1083PubMed
20.
go back to reference Santo MA, Riccioppo D, Pajecki D, Kawamoto F, de Cleva R, Antonangelo L et al (2016) Weight regain after gastric bypass: influence of gut hormones. Obes Surg 26:919–925PubMed Santo MA, Riccioppo D, Pajecki D, Kawamoto F, de Cleva R, Antonangelo L et al (2016) Weight regain after gastric bypass: influence of gut hormones. Obes Surg 26:919–925PubMed
21.
go back to reference Magro DO, Geloneze B, Delfini R, Pareja BC, Callejas F, Pareja JC (2008) Long-term Weight Regain after Gastric bypass: A 5-year Prospective Study. Obes Surg 18:648–651PubMed Magro DO, Geloneze B, Delfini R, Pareja BC, Callejas F, Pareja JC (2008) Long-term Weight Regain after Gastric bypass: A 5-year Prospective Study. Obes Surg 18:648–651PubMed
22.
go back to reference American Diabetes Association Report ADA (2018) Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018(41):S13–S27 American Diabetes Association Report ADA (2018) Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018(41):S13–S27
23.
go back to reference Kahles F, Meyer C, Möllmann J, Diebold S, Findeisen HM, Lebherz C, Trautwein C, Koch A, Tacke F, Marx N, Lehrke M (2014) GLP-1 Secretion Is Increased by Inflammatory Stimuli in an IL-6–Dependent Manner, Leading to Hyperinsulinemia and Blood Glucose Lowering. Diabetes 63(10):3221–3229PubMed Kahles F, Meyer C, Möllmann J, Diebold S, Findeisen HM, Lebherz C, Trautwein C, Koch A, Tacke F, Marx N, Lehrke M (2014) GLP-1 Secretion Is Increased by Inflammatory Stimuli in an IL-6–Dependent Manner, Leading to Hyperinsulinemia and Blood Glucose Lowering. Diabetes 63(10):3221–3229PubMed
24.
go back to reference de Souza AH, Tang J, Yadev AK et al (2020) Intra-islet GLP-1, but not CCK, is necessary for β-cell function in mouse and human islets. Sci Rep 10:2823PubMedPubMedCentral de Souza AH, Tang J, Yadev AK et al (2020) Intra-islet GLP-1, but not CCK, is necessary for β-cell function in mouse and human islets. Sci Rep 10:2823PubMedPubMedCentral
25.
go back to reference Ellingsgaard H, Hauselmann I, Schuler B et al (2011) Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17:1481–1489PubMedPubMedCentral Ellingsgaard H, Hauselmann I, Schuler B et al (2011) Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17:1481–1489PubMedPubMedCentral
26.
27.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment; insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMed Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment; insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMed
28.
go back to reference McAuley KA, Williams SM, Mann JI, Walker RJ, Lewis-Barned NJ, Temple LA et al (2001) Diagnosing insulin resistance in the general population. Diabetes Care 24:460–464PubMed McAuley KA, Williams SM, Mann JI, Walker RJ, Lewis-Barned NJ, Temple LA et al (2001) Diagnosing insulin resistance in the general population. Diabetes Care 24:460–464PubMed
29.
go back to reference Radziuk J (2000) Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab 85:4426–4433PubMed Radziuk J (2000) Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab 85:4426–4433PubMed
30.
go back to reference Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487–1495PubMed Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487–1495PubMed
31.
go back to reference Conover WJ (1998) Practical nonparametric statistics. New York: Wiley Conover WJ (1998) Practical nonparametric statistics. New York: Wiley
35.
go back to reference Stokes ME, Davis CS, Koch GG (2000) Categorical data analysis using SAS system 2nd edition. Cary Stokes ME, Davis CS, Koch GG (2000) Categorical data analysis using SAS system 2nd edition. Cary
38.
go back to reference SAS INSTITUTE Inc. SAS/STAT. User’s guide, version 9.4. Cary: SAS Institute, 2002–2012 SAS INSTITUTE Inc. SAS/STAT. User’s guide, version 9.4. Cary: SAS Institute, 2002–2012
39.
go back to reference Zilberstein B, Galvão Neto M, Ramos AC (2002) O papel da cirurgia no tratamento da obesidade. Rev Bras Med São Paulo 59(4):258–264 Zilberstein B, Galvão Neto M, Ramos AC (2002) O papel da cirurgia no tratamento da obesidade. Rev Bras Med São Paulo 59(4):258–264
40.
go back to reference Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ (2009) The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess 13(41):1-190-215–357, iii–iv. https://doi.org/10.3310/hta13410CrossRef Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ (2009) The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess 13(41):1-190-215–357, iii–iv. https://​doi.​org/​10.​3310/​hta13410CrossRef
41.
go back to reference Costa JV, Duarte JS (2006) Tecido adiposo e adipocinas. Acta Med Port 19:251–256PubMed Costa JV, Duarte JS (2006) Tecido adiposo e adipocinas. Acta Med Port 19:251–256PubMed
42.
go back to reference Sjöström L (2013) Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med 273:219–234PubMed Sjöström L (2013) Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med 273:219–234PubMed
43.
go back to reference Mango VL, Frishman WH (2006) Physiologic, psychologic, and metabolic consequences of bariatric surgery. Cardiol Rev 14(5):232–237PubMed Mango VL, Frishman WH (2006) Physiologic, psychologic, and metabolic consequences of bariatric surgery. Cardiol Rev 14(5):232–237PubMed
44.
go back to reference Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H et al (2012) Bariatric surgery and long-term cardiovascular events. JAMA 307:56–65PubMed Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H et al (2012) Bariatric surgery and long-term cardiovascular events. JAMA 307:56–65PubMed
45.
go back to reference Drucker DJ (2001) Minireview: the glucagon-like peptides. Endocrinology 142:521–527PubMed Drucker DJ (2001) Minireview: the glucagon-like peptides. Endocrinology 142:521–527PubMed
46.
go back to reference Mason EE, Ito C (1967) Gastric bypass in obesity. Surg Clin North Am 47:1345–1351PubMed Mason EE, Ito C (1967) Gastric bypass in obesity. Surg Clin North Am 47:1345–1351PubMed
49.
go back to reference Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L et al (2012) Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366:1577–1585PubMed Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L et al (2012) Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366:1577–1585PubMed
50.
go back to reference Hickey MS, Pories WJ, MacDonald KG Jr, Cory KA, Dohm GL, Swanson MS et al (1998) A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut? Ann Surg 227:637–643. discussion 643-44PubMedPubMedCentral Hickey MS, Pories WJ, MacDonald KG Jr, Cory KA, Dohm GL, Swanson MS et al (1998) A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut? Ann Surg 227:637–643. discussion 643-44PubMedPubMedCentral
51.
go back to reference Nannipieri M, Baldi S, Mari A, Colligiani D, Guarino D, Camastra S, Barsotti E, Berta R, Moriconi D, Bellini R, Anselmino M, Ferrannini E (2013) Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metab 98(11):4391–4399PubMed Nannipieri M, Baldi S, Mari A, Colligiani D, Guarino D, Camastra S, Barsotti E, Berta R, Moriconi D, Bellini R, Anselmino M, Ferrannini E (2013) Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metab 98(11):4391–4399PubMed
53.
go back to reference Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD et al (2014) Bariatric surgery versus intensive medical therapy for diabetes – 3-year outcomes. N Engl J Med 370:2002–2013PubMedPubMedCentral Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD et al (2014) Bariatric surgery versus intensive medical therapy for diabetes – 3-year outcomes. N Engl J Med 370:2002–2013PubMedPubMedCentral
54.
go back to reference Geloneze B, Tambascia MA (2006) Avaliação laboratorial e diagnóstico da resistência insulínica. Arq Bras Endocrinol Metab 50:208–215 Geloneze B, Tambascia MA (2006) Avaliação laboratorial e diagnóstico da resistência insulínica. Arq Bras Endocrinol Metab 50:208–215
55.
go back to reference Jorgensen NB et al (2012) Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metab 303:E122-131PubMed Jorgensen NB et al (2012) Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metab 303:E122-131PubMed
57.
go back to reference Bojsen-Møller KN, Dirksen C, Jørgensen NB et al (2014) Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. Diabetes 63:1725–1737PubMed Bojsen-Møller KN, Dirksen C, Jørgensen NB et al (2014) Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. Diabetes 63:1725–1737PubMed
58.
go back to reference Patti ME, McMahon G, Mun EC, Bitton A, Holst JJ, Goldsmith J et al (2005) Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 48:2236–2240PubMed Patti ME, McMahon G, Mun EC, Bitton A, Holst JJ, Goldsmith J et al (2005) Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 48:2236–2240PubMed
59.
go back to reference Kandel D, Bojsen-Moller KN, Svane MS et al (2019) Mechanisms of action of a carbohydrate-reduced, high-protein diet in reducing the risk of postprandial hypoglycemia after Roux-en-Y gastric bypass surgery. Am J Clin Nutr 110:296–304PubMed Kandel D, Bojsen-Moller KN, Svane MS et al (2019) Mechanisms of action of a carbohydrate-reduced, high-protein diet in reducing the risk of postprandial hypoglycemia after Roux-en-Y gastric bypass surgery. Am J Clin Nutr 110:296–304PubMed
60.
go back to reference Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ (2007) Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 3:597–601PubMedPubMedCentral Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ (2007) Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 3:597–601PubMedPubMedCentral
61.
go back to reference le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V et al (2006) Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243:108–114PubMedPubMedCentral le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V et al (2006) Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243:108–114PubMedPubMedCentral
62.
go back to reference Whitson BA, Leslie DB, Kellogg TA, Maddaus MA, Buchwald H, Billington CJ et al (2007) Entero-endocrine changes after gastric bypass in diabetic and nondiabetic patients: a preliminary study. J Surg Res 141:31–39PubMed Whitson BA, Leslie DB, Kellogg TA, Maddaus MA, Buchwald H, Billington CJ et al (2007) Entero-endocrine changes after gastric bypass in diabetic and nondiabetic patients: a preliminary study. J Surg Res 141:31–39PubMed
Metadata
Title
GLP-1: 10-year follow-up after Roux-en-Y gastric bypass
Authors
Camila Carvalho
Aglécio Luiz de Souza
Gisele Almeida Batista
Louise Franciscato Trivelato Duran
Débora Puzzi Fernandes
Viviane Bressane Claus Molina
Raquel Gonçalves
Joelma Silvia Giorgetti
Elintom Adami Chaim
Sarah Monte Alegre
Publication date
01-03-2022
Publisher
Springer Berlin Heidelberg
Published in
Langenbeck's Archives of Surgery / Issue 2/2022
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-021-02341-3

Other articles of this Issue 2/2022

Langenbeck's Archives of Surgery 2/2022 Go to the issue

State-of-the-Art Clinical Surgery

State-of-the-art surgery for pancreatic cancer